Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People

Set Alert for People

JHL Biotech Executives Convicted Over Trade Secrets Theft

Two former JHL Biotech executives, Racho Jordanov and Rose Lin, have been convicted in the US of conspiracy to commit trade secret theft and wire fraud after submitting plea agreements. Meanwhile, the company – now named Eden Biologics – has just announced a change of CEO.

Legal Issues Biosimilars

Who’s Hired? BIO’s Duncan Joins AAM

The Association for Accessible Medicines has appointed former Biotechnology Innovation Organization representative Joanne Duncan as its new chief operating officer.  Meanwhile, Coherus has names the new chair of its scientific advisory board, while women’s health specialist Theramex has added to its board of directors

International Executive Changes

Teva Reshuffles Top Management

Teva has announced a major management reshuffle that will see North America commercial vice-president Brendan O’Grady leave the company for a new role outside the pharmaceutical industry. Revealing his replacement, Teva also unveiled further changes.

Executive Changes Strategy

Who’s Hired? Accord’s Burt Moves On

Accord has announced the appointment of a replacement for James Burt, who has stepped down from his role as executive vice-president for the Europe, Middle East and North Africa region. Meanwhile, other organizations including NeuClone, the Medicines Patent Pool, KVK Tech and Strides have also announced executive appointments.

Executive Changes Strategy

Hikma’s Genestin Takes A Strategic Approach To BD

Business development must be treated as a “strategic tool,” with partnerships and acquisitions selected based on how they fit into the company’s bigger picture, Hikma’s newly-appointed vice-president of business development for generics Patrick Genestin tells Generics Bulletin in an exclusive interview.

Strategy Deals

Wagner Adds Germany To Role As Stada Simplifies Structure

Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

Executive Changes Strategy

Hikma Names Sandoz’ Genestin As New Generics BD Chief

Hikma has named Patrick Genestin as its new head of business development for generics, bringing to the role 25 years of experience that includes most recently a 15-year stint at Sandoz. In turn, Sandoz has looked to Teva for a successor.

Executive Changes Strategy

Neuraxpharm Recruits Another Viatris Executive To Lead European Expansion

For the second time in as many months, Neuraxpharm has looked to Viatris to recruit a top executive to help lead the CNS specialist’s continuing expansion in Europe.

Executive Changes Strategy

Who’s Hired? AAM Makes Three Key Appointments

The US Association for Accessible Medicines hires for three key leadership roles, while Australia’s Generic and Biosimilar Medicines Association has named Fresenius Kabi’s director in Australia as its newest board member. Coherus’ vice president of market access and government affairs, Thomas Nusbickel, joins CorMedix as chief commercial officer, while other major firms make board changes.

Executive Changes Strategy
See All
UsernamePublicRestriction

Register